Obstetrics, gynaecology & urinary-tract disorder

Obstetrics, gynaecology & urinary-tract disorder - commissioning policies

Please click on the links below to access the commissioning policies. The associated Equality Impact Assessments, if currently available, are accessible here.

The CCGs’ position on the implementation of policies affecting patient referral can be found here.
Assisted Conception Avanafil for erectile dysfunction Botulinum Toxin for urinary incontinence due to detrusor overactivity Cryopreservation to Preserve Fertility Dapoxetine for Premature Ejaculation Referral for the Surgical Management of Heavy Menstrual Bleeding Jaydess Levonorgestrel 13.5mg intrauterine system (IUS) for contraception Tadalafil 5mg tablets (Cialis®) for lower urinary tract symptoms (LUTS) in adult men

Safety update: Esmya® (ulipristal acetate)

Please note in February 2018 the MHRA introduced new temporary safety measures for Esmya® (ulipristal acetate) following reports of serious liver injury in women using the medicine for uterine fibroids.

This advises: do not initiate treatment in new users or those between treatment courses;  monitor liver function in current and recent users.

For more information please visit the respective Joint Formulary for South and West Devon and North and East Devon.   

Ulipristal acetate 5mg tablets (Esmya®) for intermittent treatment of uterine fibroids

Please note:  Some commissioning policies approved by the previous commissioning organisations are yet to be reviewed and updated. There is an on-going programme of work in place to review and update these policies. They will then be published under the appropriate category. 

In the meantime they are still applicable to Northern, Eastern and Western Devon CCG. Former NHS Devon policies can be accessed here

Rate this page